AI-Enhanced EEG Promises Early Alzheimer’s Detection
AI-enhanced EEG technology is emerging as a promising tool for early detection of Alzheimer's disease, potentially facilitating prevention efforts before symptoms appear.
AI-enhanced EEG technology is emerging as a promising tool for early detection of Alzheimer's disease, potentially facilitating prevention efforts before symptoms appear.
A new study identifies three sepsis subtypes and highlights ELL2 as a promising biomarker for early diagnosis and prognosis.
AI-enhanced EEG technology offers a promising, accessible way to detect early signs of Alzheimer’s disease—years before symptoms appear.
New multidisciplinary guidelines bronchoscopic lung biopsy techniques offer tissue sampling adequacy comparable to other testing methods.
QuidelOrtho and BÜHLMANN Laboratories have partnered to launch the fCAL turbo and fPELA turbo fecal biomarker assays on VITROS Systems.
Juniper Genomics has launched publicly to offer a next-generation embryo screening platform that aims to improve IVF outcomes.
rex Laboratories has launched BiomeBurden, a comprehensive test that evaluates immune responses to microbial, yeast, and mold triggers.
University of Tokyo researchers have developed a non-invasive, AI-powered imaging system that tracks platelet activity in real time.
Quest Diagnostics will offer a Fujirebio blood test this summer to enhance early detection of Alzheimer's disease.
Two studies demonstrate how AI models can significantly improve early detection of type 1 diabetes, enabling earlier intervention.
A pilot program using Healthy.io’s FDA-cleared smartphone-powered Minuteful Kidney test significantly improved CKD screening and diagnosis.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
Researchers propose developing tiny chemical sensors that detect VOCs in bodily fluids to rapidly diagnose bacterial infections.